In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 294-300

  Kanda, Yoshinobu ^a   Oshima, Kumi ^a   Kako, Shinichi ^a   Fukuda, Takahiro ^b   Uchida, Naoyuki ^c   Miyamura, Koichi ^d   Kondo, Yukio ^e   Nakao, Shinji ^e   Nagafuji, Koji ^f   Miyamoto, Toshihiro ^g   Kurokawa, Mineo ^h   Okoshi, Yasushi ⁱ   Chiba, Shigeru ⁱ   Ohashi, Yasuo ^j   Takaue, Yoichi ^k   Taniguchi, Shuichi ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHYLPREDNISOLONE; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DRUG DOSE REDUCTION; DRUG HALF LIFE; FEMALE; GOOD CLINICAL PRACTICE; HLA MATCHING; HUMAN; IN VIVO STUDY; INFUSION RELATED REACTION; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; WHOLE BODY RADIATION;

ADULT; AGED; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84875622327     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23392     Document Type: Article

References (30)

1. Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 2011;93:586-593.
2. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-2425.
3. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-1078.
4. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005;23: 9387-9393.
5. Patel B, Kirkland KE, Szydlo R, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009;94:1399-1406.
6. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934-1941.
7. Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010;28:3695-3700.
8. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426-432.
9. Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008;14:1288-1297.
10. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005;79:1351-1357.
11. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-697.
12. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011;118:2351-2357.
13. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: A Bayesian methodology for phase I cancer clinical trials. Stat Med 2001;20:2661-2681.
14. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472-476.
15. Kanda Y, Mineishi S, Saito T, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 2002;73:568-572.
16. Saito T, Kanda Y, Kami M, et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002;8:1014-1020.
17. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-1364.
18. McFarland RD, Douek DC, Koup RA, et al. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci U S A 2000;97:4215-4220.
19. Wada H, Terasako K, Kamiya Y, et al. Immune recovery after autologous PBSC transplantation without in vitro graft manipulation for refractory systemic lupus erythematosus. Bone Marrow Transplant 2011;46:1450-1454.
20. Konno A, Okada K, Mizuno K, et al. CD8alpha alpha memory effector T cells descend directly from clonally expanded CD8alpha +beta high TCRalpha beta T cells in vivo. Blood 2002;100:4090-4097.
21. Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: Evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 1999;93:3008-3016.
22. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-955.
23. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003;102:404-406.
24. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
25. Kottaridis PD, Chopra R, Chakraverty RK, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-2425.
26. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-4363.
27. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-842.
28. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121-3127.
29. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: Pharmacokinetics, GVHD, and immune reconstitution. Blood 2010;116:3080-3088.
30. Spyridonidis A, Liga M, Triantafyllou E, et al. Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transplant 2011;46:1363-1368.